Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010;162:1–11.CrossrefPubMedWeb of ScienceGoogle Scholar
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829–39.Web of ScienceCrossrefPubMedGoogle Scholar
Rotondi M, Molteni M, Leporati P, Capelli V, Marino’ M, Chiovato L. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Clin Exp Immunol 2010;162:1–11.Google Scholar
Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80–9.CrossrefWeb of ScienceGoogle Scholar
Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler 2016;22:1719–31.Web of ScienceCrossrefPubMedGoogle Scholar
Grimsey P, Frey N, Bendig G, Zitzler J, Lorenz O, Kasapic D, et al. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. Int J Pharmacokinetcs 2017;2:247–56.CrossrefGoogle Scholar
Samarasinghe S, Meah F, Singh V, Basit A, Emanuele N, Emanuele MA. Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks. Endocrine Pract 2017;23:989–98.CrossrefWeb of ScienceGoogle Scholar
About the article
Published Online: 2018-09-11
Published in Print: 2019-04-24
Author contributions: All the authors have accepted responsibility for the entire content of this submitted
manuscript and approved submission.
Research funding: None declared.
Employment or leadership: DK is a Roche Diagnostics employee.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.